Globulin helped predict weak-bone risk in one breast cancer group within a study of 1,314 women, but not as a stand-alone test. The study examined women treated at one hospital in China from 2018–2022. Researchers tested 12 computer models that looked for patterns in health records. They split the women into four groups based on cancer features. These included whether the cancer responded to hormones or had a protein called HER2. Overall, 546 women, or 41.6%, were diagnosed with osteoporosis, a condition that weakens bones. Most cases occurred in groups whose cancers responded to hormones. The strongest clues to risk differed across the four cancer groups. Globulin was a key clue in one group's best-performing model. That group had cancers without hormone receptors or the HER2 protein. Other clues included age, Platelets, the blood cells that help clotting, and Uric Acid. The model used these clues together, rather than relying on one blood result. The report gives no Globulin cutoff for bone risk. It also does not say whether higher or lower levels signaled greater risk. Finding a useful clue does not show that changing that number prevents weak bones. Results from one hospital also may not apply to everyone. For BioSocial members, this adds context rather than a new target number. Tracking Globulin alongside Bone Mineral Density could help organize your health history. When comparing notes, cancer type and treatment timing are useful context. A shared blood result alone does not mean shared bone risk. What have you noticed in your Globulin results alongside bone health checks after breast cancer treatment?